Cargando…

Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Patients with EGFR-mutant non-small cell lung cancer (NSCLC) have significantly benefited from the use of EGFR tyrosine kinase inhibitors (TKIs). However, long-term efficacy of these therapies is limited due to de novo resistance (~30%) as well as acquired resistance. Epithelial-mesenchymal transiti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yochum, Zachary A., Cades, Jessica, Wang, Hailun, Chatterjee, Suman, Simons, Brian W., O’Brien, James P., Khetarpal, Susheel K., Lemtiri-Chlieh, Ghali, Myers, Kayla V., Huang, Eric H.-B., Rudin, Charles M., Tran, Phuoc T., Burns, Timothy F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358506/ https://www.ncbi.nlm.nih.gov/pubmed/30171258 http://dx.doi.org/10.1038/s41388-018-0482-y

Ejemplares similares

Therapeutic potential of an anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma
por: Barbhuiya, Mustafa A., et al.
Publicado: (2017)

2-AG and anandamide enhance hippocampal long-term potentiation via suppression of inhibition
por: Lemtiri-Chlieh, Fouad, et al.
Publicado: (2022)

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
por: Raoof, Sana, et al.
Publicado: (2019)

Mg(2+) is a Missing Link in Plant Cell Ca(2+) Signalling and Homeostasis—A Study on Vicia faba Guard Cells
por: Lemtiri-Chlieh, Fouad, et al.
Publicado: (2020)

Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR‐mutant non‐small cell lung cancer
por: Qin, Qiong, et al.
Publicado: (2021)

Structure-Function Studies of the bHLH Phosphorylation Domain of TWIST1 in Prostate Cancer Cells()()
por: Gajula, Rajendra P., et al.
Publicado: (2015)

Alternative splicing of HER2: a novel mediator of EGFR TKI resistance
por: Yochum, Zachary A., et al.
Publicado: (2020)

Correction to targeting the EMT transcription factor snail overcomes resistance to osimertinib in EGFR‐mutant non‐small cell lung cancer
Publicado: (2023)

EMT-Induced Stemness and Tumorigenicity Are Fueled by the EGFR/Ras Pathway
por: Voon, Dominic Chih-Cheng, et al.
Publicado: (2013)

EGFR Signal-Network Reconstruction Demonstrates Metabolic Crosstalk in EMT
por: Choudhary, Kumari Sonal, et al.
Publicado: (2016)

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
por: Watanabe, Sho, et al.
Publicado: (2021)

Novel agents and strategies for overcoming EGFR TKIs resistance
por: Niu, Fei-Yu, et al.
Publicado: (2014)

Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments
por: Kwon, Yoojung, et al.
Publicado: (2019)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma
por: Hong, Xuan, et al.
Publicado: (2023)

EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer
por: Serrano, Maria J., et al.
Publicado: (2014)

Hypoxia Activated EGFR Signaling Induces Epithelial to Mesenchymal Transition (EMT)
por: Misra, Ashish, et al.
Publicado: (2012)

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
por: Zhu, Xuan, et al.
Publicado: (2019)

Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer
por: WANG, CHENGDE, et al.
Publicado: (2015)

A Guide to Transient Expression of Membrane Proteins in HEK-293 Cells for Functional Characterization
por: Ooi, Amanda, et al.
Publicado: (2016)

Emerging strategies to overcome resistance to third-generation EGFR inhibitors
por: Shi, Kunyu, et al.
Publicado: (2022)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
por: La Monica, Silvia, et al.
Publicado: (2017)

Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
por: Fassunke, Jana, et al.
Publicado: (2018)

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
por: Uchibori, Ken, et al.
Publicado: (2017)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance
por: Han, Ruoshuang, et al.
Publicado: (2021)

Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer
por: Kim, Boyeon, et al.
Publicado: (2020)

Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC
por: Li, Ling, et al.
Publicado: (2017)

Overcoming EGFR inhibitor resistance in Glioblastoma by targeting co-amplified genes
por: Pant, Ayush, et al.
Publicado: (2023)

Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer
por: Zhang, Chen, et al.
Publicado: (2021)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance
por: Gkountakos, Anastasios, et al.
Publicado: (2022)

TWIST1 a New Determinant of Epithelial to Mesenchymal Transition in EGFR Mutated Lung Adenocarcinoma
por: Pallier, Karine, et al.
Publicado: (2012)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
por: Kang, Da Hyun, et al.
Publicado: (2020)

Overcoming resistance to EGFR monotherapy in HNSCC by identification and inhibition of individualized cancer processes
por: Jubran, Maria R., et al.
Publicado: (2022)

Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
por: Novak, Jennifer, et al.
Publicado: (2022)

AKT-ions with a TWIST between EMT and MET
por: Tang, Huifang, et al.
Publicado: (2016)

HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR
por: Ingthorsson, S, et al.
Publicado: (2016)

Achyranthes bidentata polysaccharide can safely prevent NSCLC metastasis via targeting EGFR and EMT
por: Zhong, Chunlian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_683u3phc7ilm4eb6roshefbohb